DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma

Jing-Fang Zhang, Yuan-Ping Zhang, Feng-Yun Hao, Cai-Xin Zhang, Yu-Jun Li, Xiang-Rui Ji

INTRODUCTION

Gastric cancer is the second most common malignancy worldwide. Although the achievement in early diagnosis and treatment of gastric cancer has improved the patients’ outcome, it is still among the leading causes of mortality in countries such as China and Japan; even in the developed Western countries the 5-year survival rate for gastric cancer is only 10-19%[11]. The mechanisms of its development, progression, and metastasis are under investigation[2].

Breakdown of cell-cell adhesion and degradation of extracellular matrix (ECM) represent an essential step for tumor metastasis and invasion. The cadherin superfamily is a major class of adhesion molecules that play an important role in homotypic cell-cell interactions and hence cancer cell metastasis and invasion[9]. E-cadherin is a member of the cadherin family that is expressed in all epithelial cells. It is a calcium-dependent cell adhesion molecule and has been recognized as an important suppressor gene. A variety of human cancers exhibit altered expression of E-cadherin, which correlates with high grade and advanced stage of tumor.

Matrix metalloproteinases (MMPs) are a large family of matrix metalloproteinases (MMPs) that are produced by most tissues and can degrade extracellular matrix (ECM) components, such as collagens, elastin, and proteoglycans, as well as other proteins and lipids. MMPs play important roles in a variety of physiological and pathological processes, including cell migration, invasion, angiogenesis, and immune responses. They also play a crucial role in tumor progression and metastasis. E-cadherin, a member of the cadherin superfamily, is a calcium-dependent cell adhesion molecule that plays an important role in cell-cell adhesion and maintenance of epithelial morphology. E-cadherin expression is often downregulated in cancer cells, which contributes to tumor progression and metastasis.

CONCLUSION: With tumor progression and development of heterogeneity, the abnormal expressions of MMP-9, TIMP-2, and E-cadherin or DNA aneuploidy rate or high SPF gradually increases, suggesting that they play a crucial role in gastric carcinoma progression.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: MMP-9; TIMP-2; E-cadherin; DNA ploidy; Gastric carcinoma

Zhang JF, Zhang YP, Hao FY, Zhang CX, Li YJ, Ji XR. DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. World J Gastroenterol 2005; 11(36): 5592-5600
http://www.wjgnet.com/1007-9327/11/5592.asp

Abstract

AIM: To investigate DNA ploidy and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma and to explore the mechanism of invasion and metastasis of gastric carcinoma.

METHODS: Immunohistochemical methods were used to detect the expressions of MMP-9, TIMP-2, and E-cadherin in 156 cases, including 99 cases of gastric carcinoma, 16 cases of adjacent noncancerous mucosa, 16 cases of distant metastases and 25 cases of metastatic lymph node (LN) from gastric carcinoma. Flow cytometry DNA ploidy and S-phase fraction (SPF) analysis were performed on 57 cases, including 47 cases of gastric cancer, 16 cases of adjacent noncancerous mucosa, and 4 cases of distant metastatic cancer.

RESULTS: The expression of MMP-9 was significantly correlated with Lauren’s classification, Borrmann’s classification, LN metastasis, tumor metastasis, and TNM stage, as well as depth of invasion (all P<0.05). The positive rate was lower in noncancerous than in carcinoma (31.3% vs 66.7%, P<0.01). The expression of TIMP-2 was significantly correlated with Borrmann’s classification, LN metastasis, and the depth of invasion (all P<0.05). The expression of E-cadherin was significantly correlated with differentiation, Lauren’s classification, Borrmann’s classification, and LN metastasis, as well as the depth of invasion (P<0.01 or P<0.05). E-cadherin was less expressed in carcinoma than in noncarcinoma (42.4% vs 87.5%, P<0.01). There was a positive correlation between MMP-9 and TIMP-2 and a negative correlation between MMP-9 and E-cadherin, but no correlation between TIMP-2 and E-cadherin. Also there was a positive correlation between DNA aneuploid rate and differentiation and LN metastasis. SPF that was higher than 15% was positively correlated with tumor size, differentiation and LN metastasis. And there was a significant difference between carcinoma and noncarcinoma in DNA aneuploid rate and SPF.

CONCLUSION: With tumor progression and development of heterogeneity, the abnormal expressions of MMP-9, TIMP-2, and E-cadherin or DNA aneuploidy rate or high SPF gradually increases, suggesting that they play a crucial role in gastric carcinoma progression.
of zinc-dependent proteolytic enzymes, which are believed to play a pivotal role in malignant behavior of cancer cells such as rapid growth, invasion, and metastasis by degrading ECM\cite{1,2}. Increased expression of MMPs has been found in various carcinomas. The family of human MMPs comprises mainly four classes according to their structure and in vitro substrate specificity: collagenases, gelatinases, stromelysins, and membrane-type MMPs. MMP-9 belongs to gelatinases and most investigations supported that there was a positive correlation between MMP-9 and tumor progression\cite{3}. Tissue inhibitors of matrix metalloproteinases (TIMPs) are the major natural inhibitors of MMPs. To date, four types of TIMPs have been recognized\cite{4}. TIMPs are secreted proteins that are complex MMPs and are involved in the inhibition of individual MMPs and regulation of their activity. Indeed, it is thought that the balance between activated MMPs and TIMPs determines the overall MMP activity and proteolysis in vivo. However, recent experimental data suggest that TIMPs not only have MMP inhibitory functions, but also are multifunctional molecules, with apparent paradoxical effects on tumor progression. Recently some studies suggest a positive correlation between TIMP-2 level and poor outcome in certain types of tumors\cite{5,6}. In this study, we detected the expression of MMP-9, TIMP-2, and E-cadherin proteins in gastric cancer, its adjacent noncancerous mucosa, metastatic lymph nodes (LNs), and metastatic cancer by using immunohistochemical staining. Moreover we detected DNA ploidy and S-phase fraction (SPF) in gastric cancer by flow cytometry to explore the molecular and cellular mechanisms of tumor progression so as to develop novel therapies and provide scientific basis for prognostic evaluation of gastric carcinoma.

**MATERIALS AND METHODS**

**Patients and specimens**

One hundred and fifty-six surgically removed specimens from the year 2000-2003 were collected from the Department of Pathology, Affiliated Hospital of Medical College, Qingdao University, including 99 cases of gastric carcinoma, 16 cases of adjacent noncancerous mucosa, 25 cases of metastatic LNs, and 16 cases of metastatic carcinoma from gastric cancer. Patients consisted of 87 male and 28 female with a mean age of 58.2 years (range 32-82 years) and were untreated before surgery. Sections from the surgical specimens were fixed in 4% formaldehyde solution for 24-48 h, and embedded in paraffin. A 4-µm section from each specimen block was stained with H&E for histological evaluation, and representative blocks were chosen for immunohistochemical study. In addition, normal gastric epithelium, colon adenocarcinoma, and breast carcinoma were used as positive controls for E-cadherin, TIMP-2, and MMP-9, respectively. For negative controls, sections were incubated with PBS (0.01 mol/L, pH 7.4) instead of the primary antibodies.

For flow cytometry, 57 specimens were selected from immunohistochemical study cases, including 47 cases of gastric carcinoma, 6 cases of adjacent noncancerous mucosa, and 4 cases of metastatic carcinoma from gastric cancer. For each case, we selected the most representative area of the specimen for flow cytometry analysis with H&E section. Five 50-µm sections from each specimen block and one 50-µm section from normal LN block, which was fixed and embedded with the same method and used for internal standard were cut for preparation of single cell suspensions.

**Antibodies and other chemicals**

The goat anti-human polyclonal antibody against TIMP-2, rabbit anti-human monoclonal antibodies against MMP-9 and E-cadherin were from Santa Cruz (CA, USA); Histostain\textsuperscript{TM}. Plus kit was from Zymed (CA, USA); Coulter DNA-Prep Reagent kit was from Beckman Coulter (Miami, USA).

**Immunohistochemical staining**

Immunohistochemical staining was performed with SP method, according to instruction of the kit and antibodies against MMP-9, TIMP-2, and E-cadherin were used at a concentration of 1:60, 130, and 1:120, respectively.

**Sample preparation for flow cytometry analysis**

Modified Hedley protocol was a workable method for making nuclear suspensions from paraffin blocks. Sections were deparaffinized and rehydrated through changes of xylene and graded alcohol, then immersed in water, and converted to a nuclear suspension by digestion in 0.5% pepsin (pH 1.5). The dispersive nuclear suspension was pelleted by centrifugation (1 500 r/min, 5 min) and filtered through a nylon filter, and then incubated with DNA-prep reagents kit for 30 min for DNA quantitation. The exciting spectrum was 488 nm and about 20 000 signals were collected per specimen with a coefficient of variation (CV) of 2% or less. Data collection was performed on a flow cytometer (FCM, Beckman Coulter EPICS XL).

**Evaluation of immunostaining**

Clear brown staining was restricted to cytoplasm, and was considered as positive for MMP-9 and TIMP-2. Slides were scored semi-quantitatively based on staining intensity and distribution. Two investigators without knowledge of the clinical data independently performed analysis of immunohistochemical staining. Staining was graded based on the method by Massi \textit{et al}.\cite{7}, as follows: negative (-): no positive cells were found; focal (+): positive tumor cells accounted for <20% of the total; moderate (++): 21-50% of tumor cells were positive; diffuse (+++): >50% tumor cells were positive. The positive staining of E-cadherin appeared pale brown and was located in the cell membrane. Staining was scored according to the method described by Li \textit{et al}.\cite{8}: 0 score: no expression; 1 score: expression in cytoplasm; 2 scores: decreased expression; 3 scores: expression in cell membrane, namely normal expression. A score of 0-2 was considered as negative expression.

**Evaluation of flow cytometry**

FCM-derived parameters were DNA ploidy and SPF. According to DNA index (DI), aneuploid and diploid tumors were evaluated\cite{9}. Statistical analysis was performed using the $\chi^2$ test. A $P$ value lesser than 0.05 was considered as statistically significant.
All statistical analyses were performed using the SPSS 11.0 statistical software.

RESULTS

Immunohistochemical staining of MMP-9

Immunoreactivity for MMP-9 was present in the cytoplasm of neoplastic and non-neoplastic mucosa cells. MMP-9 expression showed moderate or diffuse distribution in neoplastic cells (Figure 1A), but was single or focal in noncancerous mucosa cells (Figure 1B). In the invasion front, MMP-9 showed strong positive staining (Figure 1C) and positive staining was also noted in vascular endothelial cells and inflammatory cells (Figure 1D). The expression of MMP-9 was significantly correlated with Lauren's classification (in intestinal and diffuse types, the positive rate was 58.2% and 90.9%, respectively, \( \chi^2 = 8.025, P < 0.05 \)), Borrmann's classification (in Borrmann's types I-II, III, and IV, the positive rate was 33.3%, 65.7%, and 85.0% respectively, \( \chi^2 = 7.554, P < 0.05 \)), LN metastasis (in negative and positive cases, the positive rate was 54.3% and 79.2% respectively, \( \chi^2 = 6.986, P < 0.05 \)), metastasis (in primary gastric carcinoma, metastatic LN, and metastatic carcinoma, the positive rate was 66.7%, 92.0%, and 81.7% respectively, \( \chi^2 = 7.121, P < 0.05 \)), and TNM stage (in stages II, III, and IV, the positive rate was 37.5%, 50.0%, and 73.3% respectively, \( \chi^2 = 6.647, P < 0.05 \), Tables 1 and 2). A significant association between the depth of invasion and expression of MMP-9 (in submucosa, superficial muscular layer, and deep muscular layer or serosa, the positive rate was 28.6%, 59.3%, and 73.8% respectively, \( \chi^2 = 6.743, P < 0.05 \)) was also detected. The positive rate was lower in noncarcinoma than in carcinoma (31.3% vs 66.7%, \( \chi^2 = 7.314, P < 0.01 \)).

Immunohistochemical staining of TIMP-2

Immunoreactivity for TIMP-2 was also present in the cytoplasm of neoplastic and non-neoplastic mucosa cells. TIMP-2 expression showed moderate or diffuse distribution in neoplastic cells (Figure 2A), but focal or moderate distribution in noncancerous mucosa cells (Figure 2B). The expression of TIMP-2 was significantly correlated with Borrmann's classification (in Borrmann's types I-II, III, and IV, the positive rate was 66.7%, 47.1%, and 20.0% respectively, \( \chi^2 = 6.839, P < 0.05 \)) and LN metastasis (in negative and positive cases, the positive rate was 56.5% and 32.1% respectively, \( \chi^2 = 5.992, P < 0.05 \)). A significant association between the depth of invasion and expression of TIMP-2 (in submucosa, superficial muscular layer, and deep muscular layer or serosa, the positive rate was 71.4%, 59.3%, and 33.8% respectively, \( \chi^2 = 7.417, P < 0.05 \)) was also revealed (Tables 1 and 2).

Immunohistochemical staining of E-cadherin

Immunoreactivity for E-cadherin was present in the membrane of neoplastic and non-neoplastic mucosa cells. In noncancerous mucosa epithelia, E-cadherin expression showed strong membranous staining, especially at the intercellular border (Figure 3A), but abnormal expression was observed in neoplastic tissues with reduction or loss of membranous expression and cytoplasmic or nuclear staining (Figures 3B-D). The expression of E-cadherin was significantly correlated with differentiation (in well-, moderately-, and poorly-differentiated, and signet ring cell carcinoma, the positive rate was 75.0%, 61.1%, 30.6%, and 27.6% respectively, \( \chi^2 = 14.215, P < 0.01 \)), Lauren's classification (in intestinal and diffuse type, positive rate was 75.0% and 36.8% respectively, \( \chi^2 = 11.603, P < 0.05 \)), Borrmann's classification (in Borrmann's's
Table 1 Relationship between expression of MMP-9, TIMP-2 or E-cadherin, and histopathological features in gastric carcinoma

|                           | Positive | Rate (%) |       |       |       |       |
|---------------------------|----------|----------|-------|-------|-------|-------|
|                           | n        | MMP-9    | P     | TIMP-2| P     | E-cadherin| P     |
| Differentiation           |          |          |       |       |       |       |
| Well                      | 16       | 50.0     | >0.05 | 62.5  | >0.05 | 75.0    | <0.01 |
| Moderate                  | 18       | 86.7     |       | 55.6  |       | 61.1    |       |
| Poor                      | 36       | 69.4     |       | 38.9  |       | 30.6    |       |
| Signet ring cell type     | 29       | 72.4     |       | 31.0  |       | 27.6    |       |
| Tumor recurrence          |          |          |       |       |       |       |
| Primary carcinoma         | 91       | 65.9     | >0.05 | 44.0  | >0.05 | 44.0    | >0.05 |
| Recurrent carcinoma       | 8        | 75.0     |       | 37.5  |       | 25.0    |       |
| Carcinoma and non-neoplastic |      |          |       |       |       |       |
| Gastric carcinoma         | 99       | 66.7     |       | 43.4  |       | 42.4    | <0.001|
| Non-neoplastic gastric mucosa | 16   | 31.3     |       | 31.3  |       | 87.5    |       |
| Lauren’s classification   |          |          |       |       |       |       |
| Intestinal type           | 67       | 58.2     | <0.05 | 46.3  | >0.05 | 53.7    | <0.05 |
| Diffuse type              | 22       | 90.9     |       | 36.4  |       | 13.6    |       |
| Mixed type                | 10       | 70.0     |       | 40.0  |       | 30.0    |       |
| Borrmann’s classification |          |          |       |       |       |       |
| Types I–II                | 9        | 33.3     | <0.05 | 66.7  | <0.05 | 55.6    | <0.05 |
| Type III                  | 70       | 65.7     |       | 47.1  |       | 42.9    |       |
| Type IV                   | 20       | 85.0     |       | 20.0  |       | 25.0    |       |

*P<0.05 vs diffuse type; **P<0.05 vs type IV.

Table 2 Relationships between expression of MMP-9, TIMP-2 or E-cadherin, and clinical features in gastric carcinoma

|                           | Positive | Rate (%) |       |       |       |       |
|---------------------------|----------|----------|-------|-------|-------|-------|
|                           | n        | MMP-9    | P     | TIMP-2| P     | E-cadherin| P     |
| Tumor size                |          |          |       |       |       |       |
| ≥5 cm                     | 53       | 66.0     | >0.05 | 41.5  | >0.05 | 39.6    | >0.05 |
| <5 cm                     | 46       | 67.4     |       | 45.7  |       | 45.7    |       |
| LN metastasis             |          |          |       |       |       |       |
| Negative                  | 46       | 54.3     | <0.01 | 56.5  | <0.05 | 54.3    | <0.05 |
| Positive                  | 53       | 79.2     |       | 32.1  |       | 32.1    |       |
| Metastasis                |          |          |       |       |       |       |
| Primary carcinoma         | 99       | 66.7     | <0.05 | 43.4  | >0.05 | 42.4    | >0.05 |
| Metastatic LN             | 25       | 92.0     |       | 36.0  |       | 20.0    |       |
| Metastatic carcinoma      | 16       | 81.7     |       | 43.8  |       | 37.5    |       |
| Depth of invasion         |          |          |       |       |       |       |
| Submucosa                 | 7        | 28.6     | <0.05 | 71.4  | <0.05 | 85.7    | <0.05 |
| Superficial muscular layer| 27       | 59.3     |       | 59.3  |       | 48.1    |       |
| Deep muscular layer or serosa | 65   | 73.8     |       | 33.8  |       | 35.4    |       |
| TNM stage                 |          |          |       |       |       |       |
| Stage II                  | 8        | 37.5     | <0.05 | 50.0  | >0.05 | 62.5    | >0.05 |
| Stage III                 | 16       | 50.0     |       | 43.8  |       | 50.0    |       |
| Stage IV                  | 75       | 73.3     |       | 42.7  |       | 38.7    |       |

*P<0.05 vs deep muscular layer or serosa; **P<0.05 vs stage IV.
types I-II, III, and IV, the positive rate was 66.7%, 44.3%, and 25.0% respectively, \( \chi^2 = 7.097, P<0.05 \) and LN metastasis (in negative and positive cases, the positive rate was 54.3% and 32.1% respectively, \( \chi^2 = 5.012, P<0.05 \). A significant association between the depth of invasion and expression of E-cadherin (in submucosa, superficial muscular layer, and deep muscular layer or serosa, the positive rate was 85.7%, 48.1%, and 35.4% respectively, \( \chi^2 = 7.051, P<0.05 \) was observed. E-cadherin was less expressed in carcinoma than in noncarcinoma (42.4% vs 87.5%, \( \chi^2 = 11.223, P<0.001 \), Tables 1 and 2).

**Correlation between MMP-9 and TIMP-2**

The expression of MMP-9 was significantly and positively correlated with expression of TIMP-2 (Table 3). Positive rate of TIMP-2 in cases with MMP-9 positive was higher than those with MMP-9 negative, and the coefficient of correlation was 0.22.

| MMP-9 | TIMP-2 |
|-------|--------|
| -     | +      |
| +     | 32     | 34    |
| -     | 24     | 9     |

**Correlation between E-cadherin and MMP-9**

The expression of MMP-9 was significantly and negatively correlated with the expression of E-cadherin (Table 4). Negative rate of E-cadherin in MMP-9 positive cases was higher than in MMP-9 negative cases, and the coefficient of correlation was -0.33.

| MMP-9 | E-cadherin |
|-------|------------|
| +     | -          |
| +     | 46         | 20      |
| -     | 11         | 22      |

**FCM results**

Typical DNA histogram of non-neoplastic mucosa showed a large diploid peak and a smaller tetraploid peak, and SPF was less than 15% (Figure 4A), but the histogram from gastric carcinoma showed a definitely abnormal (aneuploid or hyperdiploid) peak (Figure 4B) or/and increased SPF (Figure 4C). Aneuploid rate was significantly correlated with differentiation (in well- or moderately- and poorly-differentiated or signet ring cell carcinomas, the aneuploid rates were 42.1% and 75.0%, respectively, \( \chi^2 = 5.183, P<0.05 \) and LN metastasis (in negative and positive cases, the aneuploid rates were 80.0% and 29.4% respectively, \( \chi^2 = 11.752, \)

![Figure 3](image-url)  
**Figure 3** E-cadherin expression in gastric carcinoma. A: E-cadherin expression showed strong membranous staining in noncancerous mucosa cells, especially at the intercellular border (×400); B-D: abnormal expression was observed in neoplastic tissues which showed reduction or loss of membranous expression and showed cytoplasmic or nuclear staining (B and D, ×200; C, ×400).
It was significantly different between carcinoma and noncarcinoma (aneuploid rate were 61.7% and 16.7%, respectively, \( \chi^2 = 4.393, P<0.05 \)). SPF was significantly correlated with tumor size (the number of cases with SPF>15% and tumor size <5 cm was 9 and it was 23 in tumors with SPF>15% and tumor size >5 cm, \( \chi^2 = 4.931, P<0.05 \)), differentiation (the number of cases with SPF>15% and well- or moderately-differentiated carcinoma was 8 and it was 21 in poorly-differentiated or signet ring carcinoma, \( \chi^2 = 6.299, P<0.05 \)) and LN metastasis (the number of cases with SPF>15% and negative LN metastasis was 24 and it was 8 in cases with SPF>15% and positive LN metastasis, \( \chi^2 = 5.419, P<0.05 \)). And the number of cases with SPF higher than 15% was significantly different between carcinoma and noncarcinoma (32 vs 1, \( \chi^2 = 5.987, P<0.05 \)).

**DISCUSSION**

One of the typical characteristics of malignant tumor is invasion and metastasis, which is the main cause for their lethality. Tumor progression is considered to be a dynamic, complex, and a multi-step process, but the essential steps are the breakdown of cell-cell adhesion and degradation of basement membrane (BM) and ECM.

In the present study, immunohistochemical analysis revealed a progressive increase in expression of MMP-9 with increasing severity of lesions of carcinoma (Figure 1A). And in tumor invasion front or the surrounding of tumor nests, MMP-9 showed a strong staining (Figure 1C), while in non-neoplastic tissues it was weakly positive (Figure 1B). Although the antibodies do not distinguish between proenzyme and active forms of MMP-9, an increase in intensity of immunohistochemical reactions of MMPs may play a crucial role in the progression of carcinoma. MMP-9 upregulation will confer on tumor cells the ability to degrade BM and ECM and lead to tumor progression. MMP-9 immunoreactivity in vascular endothelial cells and inflammatory cells was also noted (Figure 1D), suggesting that those cells might secrete MMP-9 induced by malignant cells, the so-called host reaction. As reported, MMP-9 promoted inflammatory reaction by upregulation of cytokines such as IL-1\( \beta \), and this then stimulated host reaction, thus forming a pernicious cycle. Therefore, in view of MMP-9, it is not a good phenomenon that tumor cells can induce inflammatory reaction. MMP-9 participates in the whole process of carcinogenesis and development of gastric carcinoma and even in intramucosal gastric carcinomas MMP-9 showed strong staining and promoted LN metastasis, suggesting an early tumor progression. Our result demonstrated that MMP-9 activity increased as the depth of invasion extended.

![Figure 4](image)

**Table 6** Correlation between DNA ploidy or SPF and histopathological or clinical features in gastric carcinoma

|                          | n  | Aneuploid rate (%) | \( P \)  | n (SPF>15%) | \( P \)  |
|--------------------------|----|--------------------|---------|-------------|---------|
| **Tumor size**           |    |                    |         |             |         |
| \( \geq 5 \text{ cm} \) | 29 | 65.5               | >0.05   | 23          | >0.05   |
| <5 cm                    | 18 | 55.6               |         | 9           |         |
| **Differentiation**      |    |                    |         |             |         |
| Well or moderate         | 19 | 42.1               | <0.05   | 9           | <0.05   |
| Poor or signet ring cell type | 28 | 75.0               |         | 23          |         |
| **Depth of invasion**    |    |                    |         |             |         |
| Submucosa                | 7  | 28.6               | >0.05   | 3           | >0.05   |
| Muscular layer or serosa | 40 | 67.5               |         | 29          |         |
| **LN metastasis**        |    |                    |         |             |         |
| Negative                 | 30 | 80.0               | <0.001  | 24          | <0.05   |
| Positive                 | 17 | 29.4               |         | 8           |         |
| **Metastasis**           |    |                    |         |             |         |
| Primary carcinoma        | 47 | 61.7               | >0.05   | 32          | >0.05   |
| Metastatic carcinoma     | 4  | 100                |         | 3           |         |
| **Carcinoma and noncarcinoma** | | |         |             |         |
| Gastric carcinoma        | 47 | 61.7               | <0.05   | 32          | <0.05   |
| Noncarcinoma gastric mucosa | 6  | 16.7               |         | 1           |         |
indicating that MMP-9 participated in tumor invasion. It was also revealed that MMP-9 activity increased as LN metastasis progressed, indicating that MMP-9 participated in tumor metastasis. Expression rate of MMP-9 was significantly different between carcinoma and noncarcinoma (66.7% and 31.3% respectively), implying that MMP-9 may be related to carcinogenesis. Recent findings support the view that MMPs are not only responsible for the proteolytic degradation of BM as an important step in metastasis, but also essentially regulate the growth of tumor by maintaining its access to growth factors from ECM and regulation of angiogenesis[14].

Single MMP strong expression does not necessarily suggest invasion or metastasis, because its activity is influenced by its inhibitors such as RECK and TIMPs[17]. TIMPs are endogenous specific inhibitors of MMPs. They have such abilities to form tight binding, non-covalent inhibitory complexes with multiple members of the MMP family that they inhibit ECM degradation by MMPs and have anti-metastasis function[18]. TIMP-2 inhibits active and proenzyme forms of MMPs. It was reported that transfection of TIMP-2 gene into human gastric cancer cell line SGC-7901 by lipofection technology reduced their invasion potential in vivo and in vitro[19]. The expression of type IV collagenase in the untransfected group was higher than in the transfected group. The high expression of TIMP-2 may represent a mechanism by which tumor cells control the proteolysis and remodeling of ECM that occurs during invasion and progression of tumors. Another report suggested that transfection of TIMP-2 into the liver tissue could treat colorectal cancer liver metastasis[20]. However, some studies suggested that high expression level of TIMP-2 related to poor prognosis. It showed that high level of TIMP-2 mRNA correlated with the development of distant metastasis[21]. A study on gastric cancer showed that TIMP-1 and TIMP-2 were identified in 41% and 57% of tumors, respectively, whereas normal gastric mucosa was negative. No correlation was observed between the presence of TIMP-2 and tumor stage, histological type, LN status or survival[22]. However, our results demonstrated that there was correlation between the presence of TIMP-2 and depth of invasion and LN metastasis and different from MMP-9; there was no correlation between TIMP-2 and other clinical or histopathological features. Our results also suggested that as MMP-9 activity increased during tumor progression a corresponding increase in TIMP-2 level also occurred. Therefore, it appears that the expression of MMPs and TIMPs during tumor progression is coordinate regulated. Imbalance between MMP-9 and TIMP-2 could be an essential factor in tumor progression and may be more important than the concentrations of single components of MMPs and TIMPs[23,24]. The increased ratios could be interpreted as a sign of proteolytic inequilibrium in the early stage of carcinogenesis and in the advanced stage of tumor progression. We believed that the high expression of MMP-9 was the basis of tumor invasion and metastasis and that relatively high level of TIMP-2 was induced by MMP-9. Our results are contradictory to previous reports. It might be due to different study methods and antibodies used, and double effects of TIMP-2. TIMP-2 not only inhibits MMPs activities but also takes part in other activities such as cell growth and survival that cannot always be clearly reconciled with their abilities to abrogate MMP activity[25,26]. Therefore, further investigations are required to explore this controversy.

E-cadherin plays a critical role in the establishment and maintenance of intercellular adhesion, cell polarity, and tissue architecture. Abnormalities of E-cadherin adhesive system have been detected in a number of cancers. Loss of E-cadherin adhesive function has been found in premalignant conditions such as colorectal adenoma, Barrett’s esophagus, and gastric dysplasia[27] and in tumors such as ductal carcinoma in situ of the breast, prostate carcinoma, and gastric carcinoma. In gastric carcinoma, the overall expression of E-cadherin ranges from 20% up to 90% due to different score systems and different antibodies used. The present study showed that the expression rates of E-cadherin in carcinoma and noncarcinoma were 42.4% and 87.5% respectively, suggesting that E-cadherin played a role in carcinogenesis and tumor progression. The downregulation of expression of E-cadherin may contribute to disruption of normal cell-cell adhesion in malignant transformed cells, which may associate with tumor cells’ enhanced migration and proliferation, leading to invasion and metastasis. It was also revealed that the expression of E-cadherin was significantly correlated with tumor differentiation and Lauren’s classification. That is, abnormal expression rate was significantly higher in poorly differentiated (or diffuse-type) adenocarcinomas than in well-differentiated (or intestinal-type) ones, in another word, strong E-cadherin staining correlated with well-differentiated cancers and tumor cell cohesiveness, while loss of staining or changes in localization were associated with poorly differentiated, discohesive and highly invasive tumors. Multiple in vivo and in vitro studies demonstrated that a loss of E-cadherin expression correlated with the development of metastasis[28]. We proved that abnormal expression rate of E-cadherin was higher in LN metastasis positive cases than in negative ones. E-cadherin participates in the whole process from early stage to advanced stage of tumor development and in addition to its interaction with β-catenin, experimental work has also indicated that E-cadherin is involved in inducing cell-cycle arrest, at least partially, through upregulation of the cyclin-dependent kinase inhibitor, p27[29]. These interactions provide a direct link between the proliferative phenotype, presumed to be a precursor of neoplasia, and E-cadherin. It was reported[30] that the presence of paranuclear E-cadherin in cancer-associated benign epithelium suggested that alteration in E-cadherin molecule responsible for the paranuclear distribution might be an early change in gastric adenocarcinoma progression. Our result also showed the presence of paranuclear E-cadherin in cancer, especially in low-differentiated tumors (Figures 3B-D). E-cadherin has been associated with dedifferentiation, loss of adhesion and invasion in tumor cells, suggesting a role for loss of E-cadherin expression in the acquisition of potentially invasive and metastatic phenotype. Despite some contrary results, the bulk of evidence from clinical studies suggests that loss of E-cadherin is linked to prognosis and has been found to be an independent predictor in patients with various cancers[31]. Level of serum soluble E-cadherin is a potentially valid prognostic marker for gastric cancer and high concentration predicts advanced stage and indicates palliative/conservative treatment[32]. However, the reasons that E-cadherin showed strong expression in
of malignant tumors. Recent studies showed that DNA content of carcinoma cells is an independent prognostic factor. According to our investigation result that since SPF was significantly correlated with tumor size, differentiation, LN metastasis, and depth of invasion, we conclude that percentage of cells synthesizing DNA (S phase cells) is an indirect reflection of tumor proliferation, hence aggressive behavior. However, some scholars reported that SPF was not correlated with tumor differentiation. Normal or near-normal DNA modes often correlate with a high degree of histological differentiation and abnormal DNA modes with low degree of histological differentiation. In carcinoma aneuploid rate was 61.7%, much higher than in noncarcinoma (16.7%). These results indicate that the DNA pattern is a valuable predictor of early stage of cancer and prognosis. In summary, with tumor progression and development of heterogeneity, the abnormal expressions of MMP-9, TIMP-2 or E-cadherin or the rate of DNA aneuploidy or high SPF gradually increase correspondingly, suggesting that they play a crucial role in gastric carcinoma progression and can be objective markers for biological behaviors of gastric carcinoma. Furthermore, these factors correlate with one another, accelerating the process of tumor progression. In early stage of cancer or precancerous lesion, we may detect those factors to prevent tumor development and improve prognosis.

ACKNOWLEDGMENTS

The authors are grateful to the Affiliated Hospital of Medical College, Qingdao University and Qingdao Municipal Hospital, Qingdao 266003, China, for their help in accomplishing the study.

REFERENCES

1. Hansson LE, Sparen P, Nyren O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg 1999; 230: 162-169
2. Chen XY, van Der Hulst RW, Shi Y, Xiao SD, Tytgat GN, TenKate FJ. Comparison of precancerous conditions: atrophy and intestinal metaplasia in Helicobacter pylori gastritis among Chinese and Dutch patients. J Clin Pathol 2001; 54: 367-370
3. Steinberg M, McNutt P. Cadherins and their connections: adhesions have broader functions. Curr Opin Cell Biol 1999; 17: 554-560
4. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464
5. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630
6. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM. Membrane associated proteases and their inhibitors in tumor angiogenesis. J Clin Pathol 2004; 57: 577-584
7. Ravery V, Angulo F, Shaema FP, Pontes JE, Crissman JC, Fridman R. High levels of tissue inhibitor of metalloproteinases-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-1659
8. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinase: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283
9. Massi D, Fettachi A, Paglierani M, Pimpinelli N, Santucci M. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Human Pathol 2003; 34: 80-88
10 Li YJ, Ji XR. Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer. World J Gastroenterol 2003; 9: 368-372
11 Liu M, Lawson G, Delos M, Jamart J, Chatelain B, Remacle M, Marbaix E. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol 2003; 260: 25-34
12 Shen KH, Chi CW, Lo SS. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000; 20: 1307-1310
13 Opendaker G, Van den Steen PE, Dubois B, Nelsen L, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. Leukoc Biol 2001; 69: 851-859
14 Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathologic features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000; 6: 3581-3584
15 Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: 42-47
16 Egeland M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174
17 Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-3727
18 Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-2252
19 Li N, Xu C, Liu W. The effect of tissue inhibitor of metalloproteinase-2 gene (TIMP-2 gene) on gastric carcinoma cells in vitro and in vivo. Zhonghua Bingliexue Zaohi 1998; 27: 362-365
20 Brand K, Baker AH, Perez-Canto A, Possling A, Sacharaj M, Geheeb M, Arvold W. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinase-2 into the liver tissues. Cancer Res 2000; 60: 5723-5730
21 Rea AH, Floresen VA, Breg JP, Maedlandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNA for tissue inhibitors of metalloproteinases in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 1997; 3: 1623-1628
22 Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43: 791-797
23 Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19: 1589-1592
24 Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, Grano M, Quaranta M, Antonaci S. Proteolytic imbalances is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004; 109: 782-785
25 Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107: 2373-2379
26 Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392
27 Chan AO, Wong BC, Lan HY, Loke SL, Chan WK, Hui WM, Yuen YH, Ng I, Hou L, Wong WM, Yuen MF, Luk JM, Lam SK. Deregulation of E-cadherin-catenin complex in premalignant lesions of gastric adenocarcinoma. J Gastroenterol Hepatol 2003; 18: 534-539
28 Wijnhovet BF, Dinjens WN, Pignatelli M. E-cadherin-catenin cell adhesion complex and human cancer. Br J Surg 2000; 87: 992-1005
29 Rak JW, Floresen VA, Slingerland JM, Kerbel RS. E-cadherin dependent growth inhibition is mediated by the cyclin dependent kinase inhibitor p27 (KIP1). J Cell Biol 1998; 142: 557-571
30 Carpenter PM, Al-Kuran RA, Theuer CP. Paranaucal E-cadherin in gastric adenocarcinoma. Am J Clin Pathol 2002; 118: 887-894
31 Ozawa M. How do cell control the cadherin-mediated cell adhesion? Tensakakushitsu Kukusan Koso 2003; 48: 1673-1682
32 Chan AO, Chu KM, Lam SK, Wong BC, Kwork KF, Law S, Ko S, Hui WM, Yuenh YH, Wong J. Soluble E-cadherin is an independent pretherapeutic factor for long-trem survival in gastric cancer. J Clin Oncol 2003; 21: 2288-2293
33 Colpaert CG, Vermeulen PB, Benoy L, Soubry A, Van Roy F, Van Beest P, Goovaerts G, Drix LY, Van Dam P, Fox SB, Harris AL, van Marck EA. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Breast Cancer Res 2003; 18: 58-64
34 Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laroze JY, Bonnet N, Poidart JM, Mareel M, Birembaut P. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003; 105: 790-795
35 Llorens A, Rodrigo I, Lopez-Barcons L, Gonzalez-Garrigues M, Lozano E, Vinyals A, Quintanilla M, Cano A, Fahra A. Down-regulation of E-cadherin in mouse skin carcinoma cells enhance a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Laboratory Investigation 1998; 78: 1131-1138
36 Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, Miyazaki K. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 2004; 90: 1265-1273
37 Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004; 49: 179-186
38 Nawrocki-Raby B, Gilles C, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, Poidart JM, Van Roy E, Birembaut P. E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol 2003; 163: 653-661
39 Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003; 200: 39-46
40 Jiao YF, Sugai T, Suzuki M, Uesugi N, Habano W, Nakamura S, Takagane A, Suto T, Yoshida T. Application of the crypt isolation technique to the flow cytometric analysis of DNA content in gastric carcinoma. Hum Pathol 2004; 35: 587-593
41 Danesi DT, Sano M, Fabiano A, Altavista P, Pasqualetti P, Toscano MG, Antonini F, Catalano P, Mecozi A, Picconi A, Daffina A, Cuccia-Gi G. Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients. Cytophytology 2000; 42: 27-34
42 Molnar B, Boci J, Karman J, Nemeth A, Pronai L, Zagoni T, Tulassay Z. Immediate DNA ploidy analysis by endoscopy using a mechanical dissection device. Anticancer Res 2003; 23: 655-660

Science Editor Zhu LH and Guo SY Language Editor Elsevier HK